Initiate Ventures

Thanks to Brian Gormley at WSJ Pro for another piece on our Fund I launch! Read more below. #wsj #wsjpro #healthtech #techbio #venturecapital #fundlaunch

𝗗𝗲𝗹𝗶𝗴𝗵𝘁𝗲𝗱 𝘁𝗼 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝗜𝗡𝗜𝗧𝗜𝗔𝗧𝗘'𝘀 𝗙𝘂𝗻𝗱 𝗜! 🚀 We are excited to be partnering with bold founders building early-stage companies at the intersection of healthcare, life sciences, and technology. Join us to initiate the future together. Check out the full story on TechCrunch! #venturecapital #fundraise #startup #innovation #techbio #healthtech

We are excited to announce that our portfolio company, Cornerstone AI, has closed a $5M opportunistic funding round! We're thrilled to have continued our partnership with Cornerstone and their exceptional team. Their innovative approach to data cleaning is truly inspiring. Congratulations to the entire Cornerstone team on this significant milestone. We can't wait to see what you accomplish next. 🚀 https://lnkd.in/dkqKW--R #venturecapital #investment #startup #AI #datacleaning

Persana - our newest incubation - continues to receive great recognition for bringing in the future of aesthetic health. Thank you to Tatiana Boncompagni Hoover for the great feature.

Learn more about Alex Trombetta, a Principal on our team! Thanks Harry Goldberg for highlighting him as part of your HealthTech Hang member spotlight series. Feel free to reach out to us or Alex directly to hear more about the work he is doing at Initiate Ventures.

Congratulations to our portfolio company Cornerstone AI on this exciting partnership with Komodo. We can't wait to see what they accomplish together! #AI #healthcare #data #innovation #partnership

One of our three areas of focus is health tech. As a reminder, we also invest in the sectors of Precision Medicine and Biopharma Platforms (link to our thesis overview: https://lnkd.in/eEfkbAdE). The healthcare landscape is undergoing a dramatic transformation, driven by a shift towards value-based care and an increasing emphasis on the patient experience. We believe that technology is the key to unlocking a healthcare system that is both accessible and affordable. Our firm is actively investing in tech-enabled solutions that are redefining how patients receive care. We are particularly interested in companies building approaches that improve patient outcomes and drive efficiencies including those focused on: 💡 Digital platforms enabling value-based care: Innovative tools and systems using AI to deliver proactive and personalized care 💡 Novel payment frameworks: Creating innovative reimbursement models and supporting infrastructure that enable patients to benefit from cutting-edge treatments while enabling risk-sharing  💡 The consumerization of healthcare: Empowering consumers to take a more active role in their healthcare spending decisions via new solutions providing improved convenience, personalization, and pricing transparency We are seeking innovative entrepreneurs who are passionate about using technology to improve patient outcomes. If you are building a platform that is transforming healthcare delivery, we want to be your partner. Let's work together to create a healthier future. #healthcareinnovation #healthtech #valuebasedcare #accesshealthcare #venturecapital

Today, we dive into one of our key areas of focus: Biopharma platforms. As a reminder, we also invest in the sectors of Precision Medicine and Health Tech (link to our thesis overview: https://lnkd.in/eEfkbAdE). Novel technology infrastructure and computational methods are creating a new class of incumbents and driving the next wave of scientific innovation. Initiate is dedicated to investing in early-stage companies that are reimagining drug discovery and development. Some areas we are particularly interested in include:  🔍 AI-driven drug design: Leveraging artificial intelligence to identify novel drug targets, predict molecular properties, and optimize lead compounds. 🔍 Synthetic biology: Engineering living systems to produce therapeutic molecules, develop new vaccines, and create innovative drug delivery systems. 🔍 Advanced analytics: Utilizing computational approaches to deliver valuable discovery from complex biologic and clincial data, optimize clinical trial design, and accelerate regulatory approval. 🔍 Next-generation modalities: Supporting the development of innovative therapeutic approaches such as gene therapy, cell therapy, and RNA-based therapeutics. We partner with founders who are passionate about transforming biopharma paradigms and improve R&D productivity. If you are building a company that is revolutionizing the biopharmaceutical landscape, we want to hear from you. Let's work together to accelerate the path from bench to bedside. #biopharma #drugdiscovery #venturecapital #healthcareinnovation #syntheticbiology #AIindrugdiscovery #clinicaltrials #drugdevelopment 

In a previous post, we overviewed the three sectors where we invest: Precision Medicine, Biopharma Tools & Technology, and Health Tech (link to that post here: https://lnkd.in/eEfkbAdE). Here, we share more on our thesis in diagnostic platforms that elucidate molecular mechanisms of disease biology. While the field of oncology diagnostics has experienced dramatic growth (and market correction) over the last five years, we have conviction in early stage companies that aim to apply successful oncology diagnostic playbooks to other large diseases, like auto-immune, cardiometobolic, and neurologic disease. Ingredients for good-fit Seed & Series A companies include: ✅ Category-defining science in population-scale diseases with robust drug pipelines and emerging therapeutic options ✅ Commercially oriented leadership with experience generating scientific and clinical evidence that drives partnerships, adoption, and reimbursement ✅ Platforms that combine computational and biologic methods to uncover molecular mechanisms of disease and help biopharma improve drug discovery and development ✅ A clinical product vision that aligns to the incentives of physicians, payers, and patients    ✅ A capital-efficient path to revenue Are you building an early stage company with these features? We’d love to connect and learn more. #precisionmedicine #biomarkers #diagnostics #healthcareinnovation #venturecapital

Exciting news - our company Persana was featured in Allure Magazine! Persana is a testament to how Initiate brings industry and company formation expertise to world renowned clinical and scientific pioneers. We couldn't be more proud of the tremendous progress the team has made in the last few weeks. Check out the article to learn more about our groundbreaking aesthetic concierge platform built in partnership with Babak Azizzadeh, MD, FACS. We'd love to hear your thoughts! 📍 https://lnkd.in/e2ect-WV #venturestudio #aesthetics #persana #healthtech